Canadian cannabis stocks spike as U.S. reportedly set to reclassify marijuana

By: The Canadian Press Posted: 2:23 PM CDT Tuesday, Apr. 30, 2024 Last Modified: 3:53 PM CDT Tuesday, Apr. 30, 2024

TORONTO - Canadian cannabis stocks soared Tuesday afternoon after The Associated Press reported the U.S. Drug Enforcement Agency will move to reclassify marijuana as a less dangerous drug.

Read this article for free:

or

Already have an account? Log in here »

To continue reading, please subscribe:

*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.

TORONTO - Canadian cannabis stocks soared Tuesday afternoon after The Associated Press reported the U.S. Drug Enforcement Agency will move to reclassify marijuana as a less dangerous drug.

Read unlimited articles for free today:

or

Already have an account? Log in here »

Hey there, time traveller!
This article was published 30/04/2024 (873 days ago), so information in it may no longer be current.

TORONTO – Canadian cannabis stocks soared Tuesday afternoon after The Associated Press reported the U.S. Drug Enforcement Agency will move to reclassify marijuana as a less dangerous drug.

Canopy Growth Corp. closed up 80 per cent at $20.45, while Aurora Cannabis Inc. and Tilray Brands Inc. closed up 46 per cent and 40 per cent, respectively.

The Associated Press, citing five sources familiar with the matter, reported the DEA’s proposal would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than other, more dangerous drugs.

Staff work in a marijuana grow room at Canopy Growth's Tweed facility in Smiths Falls, Ont., on Thursday, Aug. 23, 2018. Canadian cannabis stocks are soaring after the U.S. Drug Enforcement Administration said it will reclassify marijuana as a less dangerous drug. THE CANADIAN PRESS/Sean Kilpatrick

However, it would not legalize marijuana for recreational use.

Currently, marijuana is listed as a Schedule I drug in the U.S., alongside heroin and LSD, but would be reclassified as a Schedule III drug, alongside ketamine and some anabolic steroids.

The reclassification of the drug in the U.S. could lessen risks for cannabis companies that operate south of the border and potentially improve investor appetite for cannabis stocks.

This report by The Canadian Press was first published April 30, 2024.

Companies in this story: (TSX:TLRY, TSX:ACB, TSX:WEED)